Evidence map›Paper›PMID 39870626›Full record

ArticleNature communications2025

Penicillin allergy as an instrumental variable for estimating antibiotic effects on resistance.

Yaki Saciuk, Daniel Nevo, Michal Chowers, Uri Obolski

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yaki SaciukDepartment of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences Tel Aviv University, Tel Aviv, Israel.
Daniel NevoDepartment of Statistics and Operations Research, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel.
Michal Chowers *Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. chowersm@tauex.tau.ac.il.ORCID http://orcid.org/0000-0001-6148-254X
Uri Obolski *Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences Tel Aviv University, Tel Aviv, Israel. uriobols@tauex.tau.ac.il.ORCID http://orcid.org/0000-0001-7594-9745

Funding

Israel Science Foundation (ISF) ISF 1286/21
6 · The paper itself

Abstract

Antibiotic resistance is influenced by prior antibiotic use, but precise causal estimates are limited. This study uses penicillin allergy as an instrumental variable (IV) to estimate the causal effect of antibiotics on resistance. A retrospective cohort of 36,351 individuals with E. coli positive urine cultures and prior outpatient antibiotic use, with outcomes assessed up to one year post-exposure, was analyzed using data from Maccabi Healthcare Services (MHS), the second-largest non-profit health fund in Israel. IV methods estimated risk differences (RD) and numbers needed to harm (NNH) for penicillin versus other antibiotics. The RD for resistance was 11.4% (95% CI: 7.6%, 15.4%) for amoxicillin/clavulanic acid, 14.1% (95% CI: 9.0%, 19.4%) for ampicillin, and 0.8% (95% CI: 0.2%, 1.4%) for piperacillin/tazobactam, with NNHs of 8.8, 7.1, and 122.0, respectively. Risks declined over time since exposure. Gentamicin, used as a negative control, showed no effect (95% CI: -2.4%, 1.8%). When directly comparing penicillin and quinolone effects on their respective AMR, penicillin use within 180 days increased resistance to amoxicillin/clavulanic acid by an RD of 17.8% (95% CI: 2.1%, 35.2%; NNH: 5.6), while quinolones raised ciprofloxacin resistance by 43.9% (95% CI: 29.9%, 59.4%; NNH: 2.3). These findings provide quantitative evidence of the impact of prior penicillin use on resistance, with implications for clinical practice and prescription policies.

Indexed as

Anti-Bacterial AgentsDrug HypersensitivityDrug Resistance, BacterialEscherichia coli InfectionsPenicillinsAdultAgedAmoxicillin-Potassium Clavulanate CombinationEscherichia coliFemaleHumansIsraelMaleMiddle AgedRetrospective StudiesYoung AdultAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsPenicillins

Identifiers

PMID39870626
PMCPMC11772653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.